Skip to main content

and
  1. Article

    Open Access

    EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

    We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the anti-EGFR agent erlotinib within the phase 3 randomised AIO-PK0104 s...

    S Boeck, A Jung, R P Laubender, J Neumann, R Egg, C Goritschan in British Journal of Cancer (2013)

  2. No Access

    Chapter

    Anti-MOG Antibodies as Early Predictors for Conversion to Relapsing-Remitting Disease Course in Patients Suggestive of Multiple Sclerosis

    Multiple sclerosis (MS) is the most common neurological disease in young adults, with the potential for subsequent chronic functional impairment and disability. MS exhibits not only heterogeneous clinical mani...

    T. Berger, P. Rubner, R. Egg, E. Dilitz in Early Indicators Early Treatments Neuropro… (2004)